Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 16/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2041767 | 0.93 | TPSAB1 (0.46) | TPSAB1CNR1HRH2 | |
| SCHEMBL2033810 | 0.91 | TPSAB1 (0.53) | TPSAB1CNR1HRH2 | |
| SCHEMBL12543612 | 0.91 | TPSAB1 (0.44) | TPSAB1CNR1HRH2 | |
| SCHEMBL2035457 | 0.91 | TPSAB1 (0.53) | TPSAB1CNR1 | |
| SCHEMBL6871198 | 0.91 | TPSAB1 (0.43) | TPSAB1HRH2 | |
| SCHEMBL2038193 | 0.90 | TPSAB1 (0.56) | TPSAB1CNR1 | |
| SCHEMBL2036133 | 0.90 | TPSAB1 (0.54) | TPSAB1CNR1 | |
| SCHEMBL12643005 | 0.90 | TPSAB1 (0.65) | TPSAB1 | |
| SCHEMBL2038443 | 0.89 | TPSAB1 (0.55) | TPSAB1CNR1 | |
| SCHEMBL2036964 | 0.89 | TPSAB1 (0.51) | TPSAB1CNR1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | TPSAB1 1/4885CNR1 160/4885HRH2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.